Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Alirocumab (Praluent) vs Captopril: Alirocumab (Praluent) has the stronger overall evidence (4.5 vs 3.5/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Alirocumab (Praluent) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Alirocumab (Praluent) and Captopril have evidence — compare verdict strength side-by-side.
Prescription dosing is 75 mg or 150 mg subcutaneously every 2 weeks (a 300 mg every-4-weeks option exists), titrated by a clinician to the LDL-C target. A prescription drug; not a self-administered supplement regimen.
any
Subcutaneous prefilled pen/syringe (alirocumab)
Off-label longevity use mirrors low antihypertensive dosing (captopril is short-acting; longer-acting ACE inhibitors like lisinopril/ramipril are often used) under a clinician. Not an approved longevity regimen; blood pressure and potassium should be monitored.
any
Oral tablet (or a longer-acting ACE inhibitor)
Within weeks
Months to years
Years
At each injection
Unknown in humans
Months to years
Years
Throughout use
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
The New England journal of medicine (2018) · Rct · n=18924
ODYSSEY OUTCOMES randomized trial of ~18,900 patients 1–12 months after acute coronary syndrome on intensive statins
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
The New England journal of medicine (2015) · Rct · n=2341
ODYSSEY LONG TERM randomized trial in high-cardiovascular-risk patients on maximally tolerated statins
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
European heart journal (2015) · Rct · n=735
Pooled ODYSSEY FH I and FH II randomized trials in 735 heterozygous familial-hypercholesterolemia patients
Angiotensin Converting Enzyme (ACE) Inhibitor Extends Caenorhabditis elegans Life Span.
PLoS genetics (2016) · Animal
ACE inhibition extended lifespan in the worm C. elegans
The ACE inhibitor captopril inhibits ACN-1 to control dauer formation and aging.
Development (Cambridge, England) (2024) · Animal
Captopril specifically inhibits the worm ACE homolog ACN-1
Control of aging by the renin-angiotensin system: a review of C. elegans, Drosophila, and mammals.
Frontiers in pharmacology (2022) · Review
Review framing RAS/ACE modulation as a conserved aging pathway
Alirocumab (Praluent) has a higher evidence score (4.5/10 vs 3.5/10) and wins in 2 of 3 categories.
For support heart health, Alirocumab (Praluent) has a higher relevance score (80 vs 62).
No known interactions between Alirocumab (Praluent) and Captopril have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.